Myocardial extracellular volume reduction is associated with improved cardiac function after SGLT2 inhibitor therapy in HFpEF
In patients with heart failure with preserved ejection fraction (HFpEF), sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve prognosis and symptoms. To evaluate the short-term effects of SGLT2i on myocardial extracellular volume (ECV) and left ventricular (LV) function in patients with HFpEF and diabetes mellit...